Online Appointment Booking
APAC · 1 shared keyword
Updated
Reviewed by Chandani Patel
APAC AI in Dermatology Market Industry Trends and Forecast to 2034: Segmented by (Application, User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$484.2 Mn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $53.9 Mn | — | — |
| 2025 (base) | $68.0 Mn | +$14.1 Mn | — |
| 2026 (forecast) | $85.8 Mn | +$17.8 Mn | +26.2% |
| 2027 (forecast) | $108.3 Mn | +$22.5 Mn | +59.3% |
| 2028 (forecast) | $136.7 Mn | +$28.4 Mn | +101% |
| 2029 (forecast) | $172.5 Mn | +$35.8 Mn | +153.7% |
| 2030 (forecast) | $217.7 Mn | +$45.2 Mn | +220.1% |
| 2031 (forecast) | $274.7 Mn | +$57.0 Mn | +304% |
| 2032 (forecast) | $346.7 Mn | +$72.0 Mn | +409.8% |
| 2033 (forecast) | $437.5 Mn | +$90.8 Mn | +543.4% |
| 2034 (forecast) | $552.2 Mn | +$114.6 Mn | +712% |
Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
| Market size, 2025 | $68.0 Mn placeholder estimate |
|---|---|
| Forecast, 2034 | $552.2 Mn placeholder estimate |
| Growth (CAGR), 2025–2034 | 26.2% placeholder estimate |
| Years | 2024 historical · 2025 base year · 2026–2034 forecast |
| Segments | Application and user (see all) |
| Key players | SkinVision, DermTech, Skin Analytics, Google Health, MetaOptima (see all) |
| Formats | PDF, PPTX, XLSX |
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
AI in dermatology analyses photos of skin to help spot skin cancer and other skin conditions.
Key segments of the AI in Dermatology market include application (Skin Cancer Detection, Chronic Skin Disease and Cosmetic Assessment) and user (Dermatologists, Primary Care and Consumers).
Advances in machine learning and large language models, more digital health data, clinician shortages and pressure to cut costs are driving the AI in Dermatology market. Health systems are moving from pilots to wider use.
Generative AI, automation of paperwork and AI tools approved as medical devices give the AI in Dermatology market strong growth, including in emerging health systems.
Concerns about accuracy, bias, privacy and liability, along with unclear regulation and the cost of fitting AI into clinical workflows, hold back the AI in Dermatology market.
The AI in Dermatology market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
In some of the countries we cover here, rules for health software come from TGA (Australia)[1], NMPA (China)[2], PMDA (Japan)[3] and MFDS (South Korea)[4]. How care is paid for in some of these countries: Medicare and the PBS (Australia)[5], basic medical insurance (China)[6], the Hospital Authority (Hong Kong)[7], Ayushman Bharat PM-JAY (India)[8], public health insurance (Japan)[9], subsidised public care (Malaysia)[10], Pharmac (New Zealand)[11], PhilHealth (Philippines)[12], MediShield Life (Singapore)[13], the Universal Coverage Scheme (Thailand)[14], JKN (BPJS Kesehatan) (Indonesia)[15], out of pocket and Sehat Sahulat (Pakistan)[16], National Health Insurance (South Korea)[17] and social health insurance (Vietnam)[18].
[1] Therapeutic Goods Administration. Checked 14 Nov 2026.
[2] National Medical Products Administration. Checked 14 Nov 2026.
[3] Pharmaceuticals and Medical Devices Agency. Checked 14 Nov 2026.
[4] Ministry of Food and Drug Safety. Checked 19 Nov 2026.
[5] Pharmaceutical Benefits Scheme. Checked 14 Nov 2026.
[6] National Healthcare Security Administration. Checked 14 Nov 2026.
[7] Hospital Authority. Checked 14 Nov 2026.
[8] National Health Authority (PM-JAY). Checked 14 Nov 2026.
[9] Ministry of Health, Labour and Welfare. Checked 14 Nov 2026.
[10] Ministry of Health Malaysia. Checked 14 Nov 2026.
[11] Pharmac. Checked 14 Nov 2026.
[12] PhilHealth. Checked 14 Nov 2026.
[13] CPF Board, MediShield Life. Checked 14 Nov 2026.
[14] National Health Security Office. Checked 14 Nov 2026.
[15] BPJS Kesehatan. Checked 19 Nov 2026.
[16] Ministry of National Health Services, Regulations and Coordination. Checked 19 Nov 2026.
[17] Health Insurance Review and Assessment Service (HIRA). Checked 19 Nov 2026.
[18] Vietnam Social Security. Checked 19 Nov 2026.
Rules on software as a medical device, data privacy (such as HIPAA and GDPR) and telehealth reimbursement shape the AI in Dermatology market. Government digital health programs in APAC are speeding up adoption.
What doctors and scientists are doing in AI in Dermatology right now, from free public sources.
Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
From our blog
APAC · 1 shared keyword
APAC · 1 shared keyword
APAC · 1 shared keyword
APAC · 1 shared keyword
APAC
APAC
Pharmaceuticals · APAC
Medical Devices · APAC
Pharmaceuticals · APAC
Healthcare Services · APAC
Pharmaceuticals · APAC
Pharmaceuticals · APAC